Adjunctive Lumateperone Improves Sexual Function in MDD Patients With Inadequate Antidepressant Response
核心洞察
Post hoc analysis of the phase 3 Study 502 found adjunctive lumateperone 42 mg improved CSFQ-14 total scores versus placebo plus antidepressant therapy in MDD patients.
At baseline, 82.5% of the 480 randomized patients met criteria for sexual dysfunction (搜索), and more than a quarter regained normal sexual function by Day 43.
Women showed statistically significant and clinically meaningful improvements, while men had numerical but non-significant gains that did not reach clinical meaningfulness.
Adding lumateperone 42 mg daily to ongoing antidepressant therapy significantly improved sexual functioning in patients with major depressive disorder (搜索) (MDD) who had an inadequate response to standard antidepressants, according to a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled Study 502 (NCT05061706).
The analysis, published in the Journal of Clinical Psychiatry, evaluated sexual function using the 14-item Changes in Sexual Functioning Questionnaire (CSFQ-14) in 480 randomized patients (lumateperone + antidepressant therapy [ADT], n=242; placebo + ADT, n=238). Lumateperone + ADT produced a statistically significant and clinically meaningful improvement in CSFQ-14 total score at Day 43 versus placebo + ADT (least squares mean difference [LSMD], 2.7; effect size [ES], 0.38; P<.0001). A 2- to 3-point change on the CSFQ total score has been suggested as clinically meaningful based on prior comparative studies of antidepressants with differing effects on sexual functioning.
Baseline Burden of Sexual Dysfunction
Sexual dysfunction (搜索) and MDD are bidirectionally linked: sexual dysfunction increases the risk of MDD, while MDD and its treatment are common causes of sexual dysfunction. Approximately 68% of patients with MDD are affected by comorbid sexual dysfunction, and sexual adverse effects of antidepressants are a leading reason patients discontinue treatment.
In Study 502, 82.5% of patients met the criteria for sexual dysfunction (搜索) at baseline (women, 85.0%; men, 76.7%). The mean age of the population was 46 years, and most patients were women (69.6%) and White (95.4%). During double-blind treatment, the most commonly administered antidepressants were SSRIs (lumateperone + ADT, 66.1%; placebo + ADT, 60.5%), followed by SNRIs (lumateperone + ADT, 27.7%; placebo + ADT, 33.6%).
Efficacy Across Subgroups
Among patients with sexual dysfunction (搜索) at baseline, lumateperone + ADT significantly improved CSFQ-14 total scores versus placebo + ADT. In women with baseline sexual dysfunction (n=142 per arm), the LSMD was 3.8 (ES, 0.50; P<.0001), meeting the threshold for clinically meaningful improvement. In men with baseline sexual dysfunction (n=56 per arm), the CSFQ-14 total score showed numerical improvement (LSMD, 2.2; ES, 0.36; P=.0975) that did not reach statistical significance.
In the overall sex-based analysis, women demonstrated significant improvement (LSMD, 3.5; ES, 0.47; P<.0001), while men showed numerical improvement (LSMD, 1.9; ES, 0.33; P=.0791) that did not meet the criteria for clinical meaningfulness. The authors cautioned that these exploratory findings should be interpreted cautiously given the post hoc nature of the analyses, lack of adjustment for multiple comparisons, and the relatively small sample size in men.
Significant improvements were observed in both younger patients under 45 years (LSMD, 3.0; ES, 0.41; P<.05) and older patients aged 45 years or older (LSMD, 3.0; ES, 0.43; P<.001).
Improvements with lumateperone + ADT were statistically significant across all CSFQ-14 domain scores at Day 43 versus placebo + ADT, including pleasure (LSMD, 0.3; ES, 0.39; P<.0001), desire/frequency (LSMD, 0.3; ES, 0.24; P<.05), desire/interest (LSMD, 0.7; ES, 0.39; P<.0001), arousal/excitement (LSMD, 0.6; ES, 0.28; P<.01), and orgasm/completion (LSMD, 0.7; ES, 0.33; P<.001). Both sexes showed significant changes in pleasure and arousal/excitement, while statistically significant improvements in desire/frequency, desire/interest, and orgasm/completion were observed in women only, with numerical improvements in men.
No Worsening in Patients Without Baseline Dysfunction
Among patients without sexual dysfunction (搜索) at baseline, CSFQ-14 total scores remained unchanged at Day 43 (LSMD, −0.4; ES, −0.10; P=.7266). A similar proportion of patients with normal sexual functioning at baseline retained it at the end of treatment in both arms (74.4% in both groups). A slightly lower proportion of patients receiving lumateperone + ADT shifted to sexual dysfunction compared with placebo + ADT (20.9% vs 25.6%), and among those with sexual dysfunction at baseline, a greater proportion receiving lumateperone + ADT improved to normal sexual function (26.3% vs 15.2%).
Primary Endpoint and Mediation Findings
The primary endpoint was met, with lumateperone + ADT producing significantly greater improvement in MADRS total score from baseline to Day 43 versus placebo + ADT in the modified intent-to-treat population (LSMD, −4.5; ES, −0.56; P<.0001). Improvements in CGI-S (LSMD, −0.5; ES, −0.51; P<.0001) and QIDS-SR-16 total score (LSMD, −2.2; ES, −0.45; P<.0001) were also significant.
Correlation analysis demonstrated a moderate association between change from baseline in MADRS total score and CSFQ-14 total score at Day 22 (r=−0.262) and Day 43 (r=−0.378). After adjusting for improvements in depressive symptoms, the effect of adjunctive lumateperone on CSFQ-14 total score was no longer statistically significant (P=.09), and an exploratory mediation analysis indicated that approximately 66.2% of the treatment effect on CSFQ-14 total score was mediated through changes in MADRS total score.
Mechanism and Clinical Context
Lumateperone is an atypical antipsychotic approved for schizophrenia, depressive episodes associated with bipolar I or II disorder, and MDD as adjunctive therapy to antidepressants. The authors note that lumateperone is a potent serotonin 5-HT2A receptor (搜索) antagonist, a dopamine D2 receptor (搜索) presynaptic partial agonist and postsynaptic antagonist, a D1 receptor–dependent indirect modulator of AMPA and NMDA currents, and a serotonin reuptake inhibitor. Across clinical studies in patients with MDD, bipolar disorder, and schizophrenia, lumateperone + ADT was not associated with increases in prolactin levels.
"While MDD is associated with sexual dysfunction (搜索) in 68% of patients, common antidepressants like selective serotonin reuptake inhibitors (SSRIs) also contribute to sexual dysfunction in approximately 70% of patients," said lead researcher Anita H. Clayton, MD, a psychiatrist at UVA Health. "This medication, recently approved by the FDA as an add-on treatment when antidepressants alone have had a limited benefit in patients with MDD, improves depressive symptoms and is not associated with medication-induced sexual dysfunction. For this reason, this treatment option may be preferable for some individuals with an inadequate MDD response who wish to avoid sexual dysfunction as a medication side effect."
Study Design and Limitations
Study 502 enrolled patients aged 18 to 65 years meeting DSM-5 criteria for MDD, with inadequate response to one or two courses of antidepressant therapy in the current depressive episode, defined as less than 50% improvement with at least 6 weeks of antidepressant monotherapy. Participants were randomized 1:1 to oral lumateperone 42 mg + ADT or placebo + ADT once daily over a 6-week double-blind treatment period, followed by a 1-week safety follow-up. The primary endpoint was change from baseline to Day 43 in MADRS total score in the modified intent-to-treat population; sexual function was evaluated in post hoc analyses based on CSFQ-14 total score in the intent-to-treat population. Overall, 89.4% of patients completed treatment.
The authors identified several limitations: the short 6-week duration may not capture long-term effects; the post hoc, exploratory nature of the analyses meant no multiplicity adjustments were performed and P values are nominal; sexual dysfunction (搜索) was assessed using self-reported measures subject to bias; sexual activity and partnership were not assessed; and the population was predominantly White with a relatively small proportion of men (approximately 30%), potentially leaving male analyses underpowered and limiting generalizability.
The study was funded by Intra-Cellular Therapies, a Johnson & Johnson company, which was responsible for the design, analysis, interpretation, and publication of the study. The findings were previously presented as a poster at the European College of Neuropsychopharmacology Annual Congress in October 2025 in Amsterdam.